Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma
Metrics: PDF 2639 views | HTML 1445 views | ?
Qi Wang1,*, Ningning Cheng2,*, Xuefei Li3, Hui Pan1, Chunyu Li4, Shengxiang Ren1, Chunxia Su1, Weijing Cai1, Chao Zhao3, Limin Zhang1, Caicun Zhou1
1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Tongji University Medical School Cancer Institute, Shanghai, 200433, P.R. China
2Department of Radiation Oncology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, 201620, P. R. China
3Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University, Tongji University Medical School Cancer Institute, Shanghai, 200433, P.R. China
4International Medical School, Tianjin Medical University, Tianjin, 300070, P.R. China
*These authors contributed equally to this work
Caicun Zhou, email: firstname.lastname@example.org
Keywords: long non-coding RNA, lung adenocarcinoma, H19, cisplatin, A549/DDP cells
Received: June 29, 2016 Accepted: November 21, 2016 Published: November 29, 2016
The acquired drug resistance would influence the efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer. The present study aimed to investigate the correlation of long non-coding RNA (lncRNA) H19 with cisplatin-resistance and clinical outcome in lung adenocarcinoma. In our study, the expression of H19 in cisplatin-resistant A549/DDP cells was unregulated. Knockdown of H19 restored the response of A549/DDP cells to cisplatin. H19-mediated chemosensitivity enhancement was associated with metastasis, induction of G0/G1 cell-cycle arrest, cell proliferation, and increased apoptosis. Furthermore, lncRNA H19 expression was significantly related to TNM stage and metastasis (P = 0.012). Overexpression of H19 was negatively correlated with cisplatin-based chemotherapy response in patients. Patients with high H19 expression exhibited a significantly shorter median progression-free survival (PFS) [4.7 months] than the low-expression patients (6.3months) [P = 0.002]. In summary, H19-mediated regulation of cisplatin resistance in human lung adenocarcinoma cells is demonstrated for the first time. H19 could potentially serve as a molecular marker to predict the clinical outcomes of lung adenocarcinoma patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.